Shin Poong Pharm

Pyronaridine-artesunate artemisinin-based combination therapy for malaria, developed with MMV and registered via the EMA; approved in 22 countries including in Europe and Africa and listed in WHO prequalification and the Essential Medicines List.

Domestically developed HMDA-crosslinked hyaluronic acid intra-articular injection given as a single 5 mL dose at six-month intervals for knee osteoarthritis; launched on 1 February 2026.

Drug candidate for acute ischemic stroke in a Korean Phase 3 trial; the Ministry of Food and Drug Safety approved an amended Phase 3 protocol in October 2026.

Production base in the Banwol industrial complex, Ansan, Gyeonggi-do: Plant 1 (finished drugs and APIs, with the central research institute) completed in 1984, Plant 2A dedicated to penicillins (2002) and Plant 2B for Pyramax built to EU GMP (2008).

Plant 3 in the Osong bio-science complex, Chungcheongbuk-do, dedicated to cephalosporin antibiotics; construction began in December 2008 with an investment of KRW 33 billion.

Launched Hyalflex Inj., a single-dose hyaluronic acid intra-articular injection given every six months.

Pyramax was listed as a treatment for domestically acquired malaria in the Korea Disease Control and Prevention Agency's malaria clinical guide (3rd edition, revised 30 March 2026), as an alternative when chloroquine is contraindicated or fails or when rapid parasite clearance is needed.

Received Ministry of Food and Drug Safety approval for an amended SP-8203 Phase 3 protocol that reflects tenecteplase (Metalyse) as a new standard thrombolytic in its exclusion criteria and methods; the trial covers 852 participants.